Federal Backing of Psychedelic Research and Developments in HPL-003 for Depression

Recent developments in federal policy have supported accelerated research into psychedelics to treat psychiatric disorders.¹ Priority vouchers were issued for developers studying psilocybin for treatment-resistant depression and major depressive disorder, along with methylone for posttraumatic stress disorder.² Psychiatric Times sat down with a pharmaceutical expert to find out more about how accelerated timelines will affect clinicians and their patients.

Psychiatric Times: What will likely be the immediate effects of the federal accelerated research initiative on psychedelics?
Eric So: The immediate effect is increased momentum. The Executive Order puts serious mental illness at the center of a national conversation and reinforces the need to move promising treatments through rigorous, FDA-led development.

For the field, that should mean more coordination across regulators, researchers and companies. For patients, the goal is simple: faster progress toward potential new options without lowering the scientific bar.

PT: What might be the largest hurdles facing psychedelic development for serious mental illness?

So: Two important hurdles exist. The first is moving from promise to proof. These therapies need to show reproducible results in well-controlled studies, durable benefit, and a clear safety profile.

The second hurdle is practicality. Treatments for serious mental illness have to work in real clinical settings. That is why Helus Pharma is focused on novel serotonergic agonists, or NSAs, designed with predictable pharmacology, manageable in-clinic treatment duration and scalable delivery in mind. Helus Pharma’s adjunctive approach is also important, because it would allow patients, if approved, to add HLP-003, its lead asset in phase 3 for major depressive disorder, without needing to come off their existing background medications, helping create a lower-friction model for providers who are prescribing and treating patients in real-world practice.

PT: How will more support for psychedelics therapies help treatment resistant patients specifically?

So: Many patients living with MDD continue to experience significant symptoms despite traditional treatments, which underscores the need for new treatment approaches. Greater federal support can help accelerate clinical research, expand awareness of trial participation opportunities, and reduce stigma by situating the study of psychedelic‑derived therapies within a rigorous, regulated medical framework.

In phase 1/2a clinical studies in inadequate responders, HLP‑003 administered with background antidepressant therapy demonstrated a clinically meaningful and statistically significant improvement compared with placebo plus antidepressant therapy, without requiring discontinuation of existing medications. These data also showed a rapid onset of antidepressant effect with durability observed over follow‑up, supporting continued evaluation of HLP‑003 in larger, well‑controlled trials.

If confirmed in phase 3, this adjunctive profile may differentiate HLP‑003 from other investigational agents that require antidepressant washout and could support its potential positioning as a second‑ or third‑line treatment option for patients with inadequate response to standard therapies.

PT: Companies developing psilocybin have been noted to receive priority vouchers. What impacts could accelerated psilocybin research have?

So: Priority vouchers are a meaningful signal that regulators recognize the need for new approaches in serious mental illness. But acceleration does not replace evidence. Companies still need rigorous trial design, strong data, and a clear benefit-risk profile.

These vouchers are also time-bound and intended to accelerate review after meaningful data are available, which makes upcoming clinical readouts especially important. For Helus Pharma, the upcoming HLP-003 phase 3 data readout in Q4 comes at an important moment for the field. If the data are supportive, that milestone could help inform future regulatory conversations around acceleration, while Helus Pharma’s existing Breakthrough Therapy Designation already provides a framework for more frequent FDA engagement, continued consultation and potential rolling review where appropriate.

Accelerated research could help clarify regulatory expectations, support earlier coordination around scheduling and access, and move the field toward responsible clinical implementation. For us as pharmaceutical developers, it also reinforces the importance of advancing beyond legacy psychedelics. HLP-003 is an intentionally created deuterated psilocin, meaning it is based on the active form that psilocybin must first be converted into by the body, is chemically modified to support additional clinical benefits, and is being developed as part of Helus Pharma’s broader NSA platform.

Mr So is interim chief executive officer and cofounder of Helus Pharma.

References

1. Duerr HA. FDA fast-tracks psychedelic therapies for depression, PTSD, and alcohol use disorder. Psychiatric Times. April 24, 2026. https://www.psychiatrictimes.com/view/fda-fast-tracks-psychedelic-therapies-for-depression-ptsd-and-alcohol-use-disorder

2. FDA accelerates action on treatments for serious mental illness following executive order. Press release. April 24, 2026. Accessed May 11, 2026. https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order